Scilex Holding Company announced that it has completed commercial manufacturing of Gloperba®?, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and is expecting to launch Gloperba®? in the U.S. in the first quarter of 2024. Scilex is expecting to launch GloperBA®?

in the U. S. in the first quarter of 2022. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex participated in the type C meeting for purposes of pre-NDA discussion with the FDA and reached agreement on a path forward to file an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica) with the FDA.